Find an Article

Filter articles

Applied Filters

Showing 131 to 140 of 274 results

‘Brexit’: time is of the essence for life sciences innovators

EU30-06-2016Laetitia Benard

The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy.

Putting the boot into biologic strategies

EU, UK30-06-2016Elizabeth Ward

Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates.

The value of secrecy for big pharma

EU23-06-2016Andy Sanderson and Ling Zhuang

While pharmaceutical companies are more likely to seek patent protection for their inventions, trade secrets can be useful too, particularly following two recent legislative developments, say Andy Sanderson and Ling Zhuang of Potter Clarkson.

Optimising IP strategies: Life Sciences Law Forum preview


Ahead of the Life Sciences Law Forum 2016, which takes place on June 23 at Etc Venues in the City of London, LSIPR previews some of the main discussion points.

Protecting homeopathic treatments in Europe

EU07-06-2016André Guder

EPO case law suggests that inventions covering homeopathic medicines do not have to meet a higher bar of patentability than conventional medicaments, but it still must be shown that the claimed products lead to the alleged therapeutic effect. André Guder of Uexküll & Stolberg reports.

Fortune favours the brave

EU06-06-2016Reuben Jacob and Fiona Kellas

Europe is not providing an adequate level of patent protection to the medical device industry, and while a solution exists, legislators need to be brave enough to abandon convention and adopt it, argue Reuben Jacob and Fiona Kellas of Jenkins.

Biotech in Birmingham: Alta Innovations’ story


Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR.

BIO 2016 session preview: “No Patent, No Cure”

EU05-06-2016Nathalie Moll

The biotech industry on both sides of the Atlantic is facing serious challenges in protecting its inventions, argues Nathalie Moll, secretary general of EuropaBio, which is organising a discussion on the topic at the 2016 BIO International Convention in San Francisco.

Greater convergence: IP and competition law

Russia03-06-2016Ilya Goryachev

In Russia, more attention is being paid towards the correlation between IP rights and competition restrictions, and pharma companies should keep abreast of developments, says Ilya Goryachev of Gorodissky & Partners.

In or out? How UK and European politics are shaking IP all about

EU, UK02-06-2016Jane Wainwright and Tom Harding

With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe.

Showing 131 to 140 of 274 results